| Year |
Citation |
Score |
| 2023 |
Vogel CL, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, Fehrenbacher L, Slamon DJ, Murphy M, Novotny WF, Burchmore M, Shak S, Stewart SJ, Press M. Efficacy and Safety of Trastuzumab as a Single Agent in First-Line Treatment of -Overexpressing Metastatic Breast Cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 41: 1638-1645. PMID 36921335 DOI: 10.1200/JCO.22.02516 |
0.36 |
|
| 2019 |
Kachuri L, Du Z, Weinhold N, Song G, Rand KA, Van Den Berg D, Hwang A, Sheng X, Hom V, Ailawadhi S, Nooka AK, Singhal S, Peters ES, Bock C, Mohrbacher A, ... ... Press M, et al. Comprehensive Investigation of White Blood Cell and Gene Expression Profiles As Risk Factors for Multiple Myeloma in African Americans Blood. 134: 4379-4379. DOI: 10.1182/Blood-2019-129298 |
0.309 |
|
| 2019 |
Press M, Seoane J, Curtis C, Quinaux E, Guzman R, Sauter G, Eiermann W, Mackey J, Robert N, Pienkowski T, Crown J, Martin M, Valero V, Bee V, Ma Y, et al. Abstract PD3-11:HER2/ERBB2status in “HER2equivocal” breast cancers by FISH and ASCO-CAP guidelines: False-positives due to heterozygous deletions of alternative control loci Cancer Research. DOI: 10.1158/1538-7445.Sabcs18-Pd3-11 |
0.431 |
|
| 2019 |
Hurvitz S, Martin M, Press M, Wijayawardana S, Brahmachary M, Ebert P, Young S, Jansen V, Slamon D. Abstract PD2-10: Treatment with abemaciclib modulates the immune response in gene expression analysis of the neoMONARCH neoadjuvant study of abemaciclib in postmenopausal women with HR+, HER2 negative breast cancer Cancer Research. 79. DOI: 10.1158/1538-7445.Sabcs18-Pd2-10 |
0.47 |
|
| 2019 |
Caswell-Jin J, McNamara K, Reiter J, Sun R, Hu Z, Ma Z, Suarez C, Tilk S, Raghavendra A, Forte V, Chin S, Bardwell H, Provenzano E, Caldas C, Lang J, ... ... Press M, et al. Abstract P3-06-01: Clonal evolution and heterogeneity in breast tumors treated with neoadjuvant HER2-targeted therapy Cancer Research. 79. DOI: 10.1158/1538-7445.Sabcs18-P3-06-01 |
0.46 |
|
| 2019 |
Chen H-, Euw EV, Millan P, Fresco R, Carrez S, Afenjar K, Fung H, Burton M, Santiago A, Guzman R, Villalobos I, Press M, Eiermann W, Slamon D. Results from TRIO030, a pre-surgical tissue-acquisition study to evaluate molecular alterations in human breast cancer tissue following short-term exposure to the androgen receptor antagonist darolutamide Annals of Oncology. 30. DOI: 10.1093/Annonc/Mdz239.076 |
0.439 |
|
| 2018 |
Ring A, Nguyen C, Smbatyan G, Tripathy D, Yu M, Press M, Kahn M, Lang JE. CBP/β-Catenin/FOXM1 Is a Novel Therapeutic Target in Triple Negative Breast Cancer. Cancers. 10. PMID 30572639 DOI: 10.3390/Cancers10120525 |
0.427 |
|
| 2018 |
Martin M, Hurvitz S, Chan D, Fernandez-Abad M, Petru E, Rostorfer R, Guarneri V, Huang C, Press M, Costigan T, Caldwell C, Wijayawardana S, Turner P, Barriga S, Slamon D. Abstract PD5-01: Final results of NeoMONARCH: A phase 2 neoadjuvant study of abemaciclib in postmenopausal women with hormone receptor positive (HR+), HER2 negative breast cancer (BC) Cancer Research. 78. DOI: 10.1158/1538-7445.Sabcs17-Pd5-01 |
0.49 |
|
| 2018 |
Prat A, Slamon D, Hurvitz S, Press M, Phillips GL, Valverde VL, Kiermaier A, Helms H, Martin M, Haas Sd. Abstract PD3-06: Association of intrinsic subtypes with pathological complete response (pCR) in the KRISTINE neoadjuvant phase 3 clinical trial in HER2-positive early breast cancer (EBC) Cancer Research. 78. DOI: 10.1158/1538-7445.Sabcs17-Pd3-06 |
0.532 |
|
| 2018 |
Wu N, Wong E, Acca B, Birkmeier J, Tran L, Zhao S, Wong W, Chu V, Ho K, Malek M, Lu C, Ge G, David K, Quigley N, Beqaj S, ... ... Press M, et al. Abstract P2-03-03: A multicenter clinical study of Xpert® breast cancer STRAT4 demonstrates high concordance with central lab ER, PgR, HER2, and Ki67 IHC and HER2 FISH tests in FFPE breast tumor tissues Cancer Research. 78. DOI: 10.1158/1538-7445.Sabcs17-P2-03-03 |
0.539 |
|
| 2017 |
Hurvitz S, Martin M, Abad MF, Chan D, Rostorfer R, Petru E, Barriga S, Costigan T, Caldwell C, Nguyen T, Press M, Slamon D. Abstract S4-06: Biological effects of abemaciclib in a phase 2 neoadjuvant study for postmenopausal patients with HR+, HER2- breast cancer Cancer Research. 77. DOI: 10.1158/1538-7445.Sabcs16-S4-06 |
0.514 |
|
| 2017 |
Haas Sd, Hurvitz S, Martin M, Kiermaier A, Phillips GL, Xu J, Helms H, Slamon D, Press M. Abstract P6-07-09: Biomarker analysis from the neoadjuvant KRISTINE study in HER2-positive early breast cancer (EBC) Cancer Research. 77. DOI: 10.1158/1538-7445.Sabcs16-P6-07-09 |
0.511 |
|
| 2017 |
Hanf D, Fasching P, Villalobos I, Gasparyan A, Wachter D, Santiago A, Guzman R, Weihbrecht S, Hanf V, Hartmann A, Beckmann M, Press M. Abstract P4-12-07:CCND1amplification in early breast cancer patients: Correlation with subtypes and prognosis Cancer Research. 77. DOI: 10.1158/1538-7445.Sabcs16-P4-12-07 |
0.493 |
|
| 2017 |
Wu N, Wong W, Ho K, Chu V, Rizo A, Davonport S, Kelly D, Makar R, Jassem J, Duchnowska R, Biernat W, Radecka B, Fujita T, Klein J, Stonecypher M, ... ... Press M, et al. Abstract P1-03-03: High concordance of ER, PR, HER2 and Ki67 by central IHC and FISH with mRNA measurements by GeneXpert® breast cancer stratifier assay Cancer Research. 77. DOI: 10.1158/1538-7445.Sabcs16-P1-03-03 |
0.492 |
|
| 2016 |
Slamon D, Eiermann W, Robert N, Giermek J, Martin M, Jasiowka M, Mackey J, Chan A, Liu M, Pinter T, Valero V, Falkson C, Fornander T, Shiftan T, Bensfia S, ... ... Press M, et al. Abstract S5-04: Ten year follow-up of BCIRG-006 comparing doxorubicin plus cyclophosphamide followed by docetaxel (AC→T) with doxorubicin plus cyclophosphamide followed by docetaxel and trastuzumab (AC→TH) with docetaxel, carboplatin and trastuzumab (TCH) in HER2+ early breast cancer Cancer Research. 76. DOI: 10.1158/1538-7445.Sabcs15-S5-04 |
0.5 |
|
| 2016 |
Mackey J, Lipatov O, Martín M, Webster M, Hegg R, Verma S, Ramos-Vázquez M, Fresco R, Thireau F, Houé V, Press M, Kumaran M, Damaraju S. Abstract P6-14-03: Genome wide association study (GWAS) to identify variants conferring ramucirumab-associated hypertension in the ROSE/TRIO-012 breast cancer trial Cancer Research. 76. DOI: 10.1158/1538-7445.Sabcs15-P6-14-03 |
0.413 |
|
| 2016 |
Nuciforo P, Thyparambil S, Galván P, Vilaro M, Jimenez J, Liao W, Cecchi F, Blackler A, Press M, Gagnon R, Ellis C, Hembrough T, Johnston S, Prat A. Abstract P3-07-08: Quantitative HER family proteins assessment as prognostic and predictive biomarkers in the EGF30008 clinical trial Cancer Research. 76. DOI: 10.1158/1538-7445.Sabcs15-P3-07-08 |
0.486 |
|
| 2016 |
Prat A, Cheang M, Galván P, Nuciforo P, Paré L, Adamo B, Viladot M, Press M, Gagnon R, Ellis C, Johnston S. Abstract P2-08-16: Prognostic and predictive abilities of intrinsic subtype in hormone receptor-positive metastatic breast cancer from the EGF30008 phase III clinical trial Cancer Research. 76. DOI: 10.1158/1538-7445.Sabcs15-P2-08-16 |
0.538 |
|
| 2013 |
Slamon D, Swain S, Buyse M, Martin M, Geyer C, Im Y, Pienkowski T, Kim S, Robert N, Steger G, Crown J, Verma S, Eiermann W, Costantino J, Im S, ... ... Press M, et al. Abstract S1-03: Primary results from BETH, a phase 3 controlled study of adjuvant chemotherapy and trastuzumab ± bevacizumab in patients with HER2-positive, node-positive or high risk node-negative breast cancer Cancer Research. 73. DOI: 10.1158/0008-5472.Sabcs13-S1-03 |
0.473 |
|
| 2013 |
Lee C, Davies L, Gebski V, Lord S, Leo AD, Johnston S, Geyer C, Cameron D, Press M, Ellis C, Simes J, deSouza P. Abstract P1-08-14: HER2 extracellular domain (ECD): A predictive marker of lapatinib treatment benefit in advanced breast cancer Cancer Research. 73. DOI: 10.1158/0008-5472.Sabcs13-P1-08-14 |
0.506 |
|
| 2012 |
Christiansen J, Barakat N, Murphy D, Rimm D, Dabbas B, Nerenberg M, Beruti S, Quinaux E, Hall J, Press M, Slamon D. Abstract PD02-01: Her2 expression measured by AQUA analysis on BCIRG-005 and BCIRG-006 predicts the benefit of Herceptin therapy Cancer Research. 72. DOI: 10.1158/0008-5472.Sabcs12-Pd02-01 |
0.464 |
|
| 2011 |
Slamon D, Eiermann W, Robert N, Pienkowski T, Martin M, Press M, Mackey J, Glaspy J, Chan A, Pawlicki M, Pinter T, Valero V, Liu MC, Sauter G, von Minckwitz G, et al. Adjuvant trastuzumab in HER2-positive breast cancer. The New England Journal of Medicine. 365: 1273-83. PMID 21991949 DOI: 10.1056/Nejmoa0910383 |
0.48 |
|
| 2011 |
Eiermann W, Pienkowski T, Crown J, Sadeghi S, Martin M, Chan A, Saleh M, Sehdev S, Provencher L, Semiglazov V, Press M, Sauter G, Lindsay MA, Riva A, Buyse M, et al. Phase III study of doxorubicin/cyclophosphamide with concomitant versus sequential docetaxel as adjuvant treatment in patients with human epidermal growth factor receptor 2-normal, node-positive breast cancer: BCIRG-005 trial. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 3877-84. PMID 21911726 DOI: 10.1200/Jco.2010.28.5437 |
0.477 |
|
| 2011 |
Dieli-Conwright CM, Sullivan-Halley J, Patel A, Press M, Malone K, Ursin G, Burkman R, Strom B, Simon M, Weiss L, Marchbanks P, Folger S, Spirtas R, Deapen D, Bernstein L. Does hormone therapy counter the beneficial effects of physical activity on breast cancer risk in postmenopausal women? Cancer Causes & Control : Ccc. 22: 515-22. PMID 21213036 DOI: 10.1007/S10552-010-9719-Y |
0.376 |
|
| 2010 |
Dieli-Conwright C, Sullivan-Halley J, Patel A, Press M, Malone K, Ursin G, Burkman R, Strom B, Simon M, Bernstein L. Abstract 5739: Lifetime recreational physical activity, hormone therapy use and breast cancer risk in postmenopausal women Cancer Research. 70: 5739-5739. DOI: 10.1158/1538-7445.Am10-5739 |
0.384 |
|
| 2010 |
Perez E, Dueck A, Press M, Chen B, Jenkins R, Paik S, Kim C, Wiktor A, Meyer R, Ketterling R, Villalobos I, Finnigan M, Buyse M, Zujewski J, Shing M, et al. Abstract PD10-02: Round-Robin Review of HER2 Testing in the Context of Adjuvant Therapy for Breast Cancer (NCCTG N9831/BCIRG006/BCIRG005) Cancer Research. 70. DOI: 10.1158/0008-5472.Sabcs10-Pd10-02 |
0.441 |
|
| 2010 |
Nuciforo P, Burzykowski T, Lambertini C, Gardner H, Liu W, Lee B, Barzaghi-Rinaudo P, Rheinhardt J, Barrett C, Linnartz R, Dugan M, Hackl W, Eiermann W, Pienkowski T, Crown J, ... ... Press M, et al. Abstract P3-10-24: Fibroblast Growth Factor Receptor 1 Amplification and Overexpression in Breast Cancer Tissue Microarrays Using Chromogenic In Situ Hybridization and Immunohistochemistry Cancer Research. 70. DOI: 10.1158/0008-5472.Sabcs10-P3-10-24 |
0.525 |
|
| 2009 |
O'Rourke L, Pegram M, Press M, Pippen J, Pivot X, Gomez H, Florance A, Maltzman J, Johnston S, Johnston S. First-line lapatinib combined with letrozole versus letrozole alone for hormone receptor positive (HR+) metastatic breast cancer (MBC): Subgroup analyses of borderline FISH+, IHC 2+, HER2 unknown (UNK), and treatment-naive (TN) populations from EGF30008. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 1062. PMID 27961166 DOI: 10.1200/Jco.2009.27.15_Suppl.1062 |
0.483 |
|
| 2009 |
Finn RS, Press M, Dering J, Florance A, Platek G, Arbushites M, Koehler M, Johnston S. Progression-free survival (PFS) of patients with HER2-negative, estrogen-receptor (ER)-low metastatic breast cancer (MBC) with the addition of lapatinib to letrozole: Biomarker results of EGF30008. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 1018. PMID 27960731 DOI: 10.1200/Jco.2009.27.15_Suppl.1018 |
0.473 |
|
| 2009 |
Platek GT, Koehler M, Gagnon R, O'Rourke L, Maltzman JD, Press M, Johnston S, Pegram M. Relevance of serum HER2 extracellular domain (sECD) in EGF30008, a study of letrozole ± lapatinib in patients (pts) with hormone-receptor positive (HR+) metastatic breast cancer (MBC). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 1019. PMID 27960730 DOI: 10.1200/Jco.2009.27.15_Suppl.1019 |
0.483 |
|
| 2009 |
Gray J, Das D, Spellman P, Wang N, Kuo W, Wyrobek A, Bhattacharya S, Press M, Leo AD, Ellis C, Arbushites M, Casey M, Gagnon R, Koehler M. A 6 gene molecular predictor of lapatinib related benefit: from cell line models to clinical trials. Cancer Research. 69: 58. DOI: 10.1158/0008-5472.Sabcs-58 |
0.402 |
|
| 2009 |
Johnston S, Pegram M, Press M, Pippen J, Pivot X, Gomez H, Florance A, O'Rourke L, Maltzman J. Lapatinib combined with letrozole vs. letrozole alone for front line postmenopausal hormone receptor positive (HR+) metastatic breast cancer (MBC): first results from the EGF30008 Trial. Cancer Research. 69: 46. DOI: 10.1158/0008-5472.Sabcs-46 |
0.517 |
|
| 2009 |
Johnston S, O'Rouke L, Wang W, Pegram M, Press M, Maltzman J. Baseline serum extracellular domain HER2 expression in hormone receptor-positive metastatic breast cancer: correlation with known tissue HER2 status. Cancer Research. 69: 3147. DOI: 10.1158/0008-5472.Sabcs-3147 |
0.527 |
|
| 2009 |
Johnston S, O'Rourke L, Wang W, Pegram M, Press M, Maltzman J. Correlation of tumor burden, liver and bone metastasis with serum extracellular domain HER2 expression in front-line metastatic breast cancer. Cancer Research. 69: 3146. DOI: 10.1158/0008-5472.Sabcs-3146 |
0.428 |
|
| 2009 |
Haque R, Press M, Polikoff J, Avila C, Enger S. HER2/ER subtypes associated with patient and tumor factors and predicted survival among participants in a retrospective breast cancer cohort study in Southern California. Cancer Research. 69: 3099. DOI: 10.1158/0008-5472.Sabcs-3099 |
0.557 |
|
| 2009 |
Slamon D, Eiermann W, Robert N, Pienkowski T, Martin M, Rolski J, Chan A, Mackey J, Liu M, Pinter T, Valero V, Falkson C, Fornander T, Shiftan T, Olsen S, ... ... Press M, et al. Phase III Randomized Trial Comparing Doxorubicin and Cyclophosphamide Followed by Docetaxel (AC→T) with Doxorubicin and Cyclophosphamide Followed by Docetaxel and Trastuzumab (AC→TH) with Docetaxel, Carboplatin and Trastuzumab (TCH) in Her2neu Positive Early Breast Cancer Patients: BCIRG 006 Study. Cancer Research. 69: 62-62. DOI: 10.1158/0008-5472.Sabcs-09-62 |
0.51 |
|
| 2009 |
Gardner H, Nuciforo P, Liu W, Lee B, Rheinhardt J, Barrett C, Linnartz R, Dugan M, Eiermann W, Pienkowski T, Martin M, Robert N, Forbes J, Buyse M, Finn R, ... ... Press M, et al. PI3 Kinase Pathway Analysis in Tissue Microarrays Using Laser Capture Microdissection and Immunohistochemistry. Cancer Research. 69: 4043-4043. DOI: 10.1158/0008-5472.Sabcs-09-4043 |
0.337 |
|
| 2008 |
Cameron D, Casey M, Press M, Lindquist D, Pienkowski T, Romieu CG, Chan S, Jagiello-Gruszfeld A, Kaufman B, Crown J, Chan A, Campone M, Viens P, Davidson N, Gorbounova V, et al. A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses. Breast Cancer Research and Treatment. 112: 533-43. PMID 18188694 DOI: 10.1007/S10549-007-9885-0 |
0.54 |
|
| 2006 |
Finn RS, Dering J, Ginther C, Press M, Forbes J, Mackey J, French T, South M, Rupin M, Slamon DJ. ER+ PR- breast cancer defines a unique subtype of breast cancer that is driven by growth factor signaling and may be more likely to respond to EGFR targeted therapies Journal of Clinical Oncology. 24: 514-514. DOI: 10.1200/Jco.2006.24.18_Suppl.514 |
0.505 |
|
| 2004 |
Enger SM, Greif JM, Polikoff J, Press M, O'Connell TX, Esserman L, De Virgilio C, Johnson NM, Wagman LD. Body weight correlates with mortality in early-stage breast cancer Archives of Surgery. 139: 954-960. PMID 15381612 DOI: 10.1001/Archsurg.139.9.954 |
0.508 |
|
| 2004 |
Meeske K, Press M, Patel A, Bernstein L. Impact of reproductive factors and lactation on breast carcinoma in situ risk. International Journal of Cancer. 110: 102-9. PMID 15054874 DOI: 10.1002/Ijc.20072 |
0.47 |
|
| 2003 |
Formenti SC, Volm M, Skinner KA, Spicer D, Cohen D, Perez E, Bettini AC, Groshen S, Gee C, Florentine B, Press M, Danenberg P, Muggia F. Preoperative twice-weekly paclitaxel with concurrent radiation therapy followed by surgery and postoperative doxorubicin-based chemotherapy in locally advanced breast cancer: a phase I/II trial. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 21: 864-70. PMID 12610186 DOI: 10.1200/Jco.2003.06.132 |
0.386 |
|
| 2002 |
Press M, Spaulding B, Groshen S, Kaminsky D, Hagerty M, Sherman L, Christensen K, Edwards DP. Comparison of different antibodies for detection of progesterone receptor in breast cancer. Steroids. 67: 799-813. PMID 12123792 DOI: 10.1016/S0039-128X(02)00039-9 |
0.412 |
|
| 2002 |
Formenti SC, Spicer D, Skinner K, Cohen D, Groshen S, Bettini A, Naritoku W, Press M, Salonga D, Tsao-Wei D, Danenberg K, Danenberg P. Low HER2/neu gene expression is associated with pathological response to concurrent paclitaxel and radiation therapy in locally advanced breast cancer. International Journal of Radiation Oncology, Biology, Physics. 52: 397-405. PMID 11872285 DOI: 10.1016/S0360-3016(01)02655-4 |
0.525 |
|
| 2002 |
Vogel CL, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, Fehrenbacher L, Slamon DJ, Murphy M, Novotny WF, Burchmore M, Shak S, Stewart SJ, Press M. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 20: 719-26. PMID 11821453 DOI: 10.1200/Jco.20.3.719 |
0.485 |
|
| 1997 |
Formenti SC, Dunnington G, Uzieli B, Lenz H, Keren-Rosenberg S, Silberman H, Spicer D, Denk M, Leichman G, Groshen S, Watkins K, Muggia F, Florentine B, Press M, Danenberg K, et al. Original p53 status predicts for pathological response in locally advanced breast cancer patients treated preoperatively with continuous infusion 5-fluorouracil and radiation therapy. International Journal of Radiation Oncology, Biology, Physics. 39: 1059-68. PMID 9392545 DOI: 10.1016/S0360-3016(97)00506-3 |
0.516 |
|
| 1993 |
Sauer MV, Miles RA, Dahmoush L, Paulson RJ, Press M, Moyer D. Evaluating the effect of age on endometrial responsiveness to hormone replacement therapy: A histologic ultrasonographic, and tissue receptor analysis Journal of Assisted Reproduction and Genetics. 10: 47-52. PMID 8499679 DOI: 10.1007/Bf01204440 |
0.311 |
|
| Show low-probability matches. |